To sum up, our study provided the first evidence that deoxyshikonin exerted anti-tumor and anti-glycolytic activities in AML cells by suppressing PKM2 via inactivation of the Akt/mTOR signaling. This evidence concerns the gene AKT1 and neoplasm.